[Please note that this page contains affiliate links. If you choose to purchase after clicking a link, I may receive a commission at no extra cost to you.]
New research reveals the beneficial effects of cannabinoids in helping to manage colon cancer, as two recent studies may have found that cannabinoids can reduce cell growth for colon cancer, reports Forbes.
Although the studies were limited to cell culture and cell model methodologies, their research may indicate that cannabinoids can be promising for further studies into therapies for what is the third most common cancer diagnosis in the US, the American Cancer Society.
A combination of mushroom extracts and cannabis created an oncological product from the biomedical company Cannabotech.
Cannabotech, for their study, found that they could reduce over 90% of colon cancer cells using their “integrative-colon” products.
THC and psilocybin were eliminated from their research because of regulation complications in getting products with psychoactive compounds to the market. Although, stunting the growth of colon cancer cells was done by using CBD and other cannabinoid derivatives.
For now, the study is limited to a cell model, which was done by researchers associated with pharmaceutical companies. After that, however, the researchers hope to see their results replicated in animal studies.
Further studies published in the journal International Immunopharmacology were found to use human colorectal cell lines, including disease and health cell lines, to study the effects of the cannabinoids.
They found that CBD and other cannabinoids reduced cancer cells’ increased cancer cell death and its ability to function through the process called apoptosis. In addition, it interrupted the cell cycle for human colorectal cancer cells.
Their findings were receptor-specific, which means that the data only supports CBD as potential “a potent and safe therapy for people with CB2-bearing colorectal cancer,” writes the researchers.
“Because of the limits of in vitro studies, it seems necessary to do a deep mechanistic study concerning CB2-dependent pathways for colon cancer animal models to increase our understanding into CBD’s mechanism of its effects.”